Gehui Ni

Gehui Ni

Auto-generated profile, based on publicly available information

Gehui Ni

The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in Cardiovascular Diagnosis and Therapy
Verified
Journal Article
Open access
PDF file
YYYan Yan
Yan Yan
YXYing Xu
Ying Xu
GNGehui Ni
Gehui Ni
SWSiqi Wang
Siqi Wang
XLXinli Li
Xinli Li
HZHaifeng Zhang
Haifeng Zhang
Background: Aberrant vascular smooth muscle cell (VSMC) proliferation and migration play an important role in the development of cardiovascular diseases including pulmonary arterial hypertension (PAH). MicroRNAs (miRNAs, miRs) have been considered to be implicated in the progression of PAH pathogenesis. In this study, we aim to clarify the role of miR-221 on proliferation and migration of pulmonary arterial smooth muscle cells (PASMCs) and identify the target genes involved in this biological process. Methods: PASMCs were isolated from the pulmonary arteries of male Sprague-Dawley (SD) rats. Cell proliferation of PASMCs was detected by 5-ethynyl-2'-deoxyuridine (EdU) assay. Cell migration was determined by a scratch wound assay. Quantitative real-time PCR was used to determine the expression of miR-221 while western blot analysis was used to determine the expression of TIMP3. Luciferase assay was used to confirm that TIMP3 was a direct target gene of miR-221. Monocrotaline (MCT) induced-PAH rat model was established and miR-221 and TIMP3 levels were checked in lung tissue and PASMCs from PAH rats. Results: miR-221 was able to promote the proliferation and migration PASMCs. TIMP3 were negatively regulated by miR-221 at the protein level in PASMCs. In addition, TIMP3 was identified to be a direct target gene of miR-221 in PASMCs based on luciferase assays. TIMP3 knockdown abolished the inhibitory effect of miR-221 inhibitor on PASMCs proliferation and migration, suggesting TIMP3 mediated the effects of miR-221 in PASMCs. Finally, we found that miR-221 was increased while TIMP3 was down-regulated in PASMCs in MCT-treated rats. Conclusions: In conclusion, miR-221 promotes PASMCs proliferation and migration by targeting TIMP3. MiR-221 and TIMP3 could be potential therapeutic targets for the treatment of PAH.

3 June 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
ICIokfai Cheang
Iokfai Cheang
XZXu Zhu
Xu Zhu
XLXinyi Lu
Xinyi Lu
YLYing Li
Ying Li
GNGehui Ni
Gehui Ni
XLXinli Li
Xinli Li
Background: Anthracycline‐based chemotherapy is a vital treatment for various cancers but carries notable risks of cardiotoxicity. This study aimed to assess how different body mass index values and glycemic status influence the risk of major adverse cardiovascular events (MACE) in chemotherapy‐naïve adult patients with cancer treated with anthracyclines. Methods: This retrospective cohort included 11 393 chemotherapy‐naïve patients who initiated anthracycline‐based chemotherapy between 2000 and 2019. Follow‐up began from the first anthracycline dose. Body mass index was categorized as underweight/normal weight (<25 kg/m 2 ), overweight (25–29.9 kg/m 2 ), and obese (≥30 kg/m 2 ). Glycemic status was classified as normoglycemic or diabetes/prediabetes (diabetes: hemoglobin A1c ≥6.5% or fasting glucose ≥126 mg/dL; prediabetes: hemoglobin A1c 5.7%–6.4% or fasting glucose 100–125 mg/dL). Results: Over a median follow‐up of 8.7 years, 985 (8.64%) patients experienced MACE. Obesity was significantly associated with an increased risk of MACE (hazard ratio [HR], 1.38 [95% CI, 1.10–1.73], reference: underweight/normal weight) and heart failure hospitalization, and diabetes/prediabetes also significantly predicted MACE (HR, 1.28 [95% CI, 1.10–1.50], reference: normoglycemic). Notably, overweight (HR, 0.85 [95% CI, 0.80–0.91]) and obesity (HR, 0.85 [95% CI, 0.74–0.96]) were associated with lower risk of all‐cause mortality. Joint analysis revealed that patients with both obesity and diabetes/prediabetes had the highest risk of MACE (HR, 1.74 [95% CI, 1.28–2.37]) and heart failure hospitalization (HR, 1.99 [95% CI, 1.41–2.81]). Conclusions: In patients with cancer undergoing anthracycline‐based chemotherapy, both body mass index and glycemic status significantly affect cardiovascular risks, with the highest risk observed in those with concurrent obesity and diabetes/prediabetes, emphasizing the need for tailored risk assessment and management.